期刊
CELL STEM CELL
卷 10, 期 1, 页码 16-28出版社
CELL PRESS
DOI: 10.1016/j.stem.2011.12.013
关键词
-
资金
- NIH [DP2OD004437, RC1AG036142, R33HL089027]
- California Institute of Regenerative Medicine [RB3-05219]
- Burroughs Wellcome Foundation
Cardiovascular disease is a leading cause of death worldwide. The limited capability of heart tissue to regenerate has prompted methodological developments for creating de novo cardiomyocytes, both in vitro and in vivo. Beyond uses in cell replacement therapy, patient-specific cardiomyocytes may find applications in drug testing, drug discovery, and disease modeling. Recently, approaches for generating cardiomyocytes have expanded to encompass three major sources of starting cells: human pluripotent stem cells (hPSCs), adult heart-derived cardiac progenitor cells (CPCs), and reprogrammed fibroblasts. We discuss state-of-the-art methods for generating de novo cardiomyocytes from hPSCs and reprogrammed fibroblasts, highlighting potential applications and future challenges.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据